Connect with us

Press Release

The New America Created by Miles Yu: Burning Anti-Asian Hate

Published

5 years ago

on

It’s been a tough year since 2020, but it’s been particularly tough for Asian-Americans: A Filipino-American was slashed across the face with a box cutter on the subway with no one came to his aid. The wound required a hundred stitches. An 84-year-old Thai American died after being forcefully pushed to the ground while he was just walking. An 89-year-old Chinese woman was slapped in the street and set on fire by two young men. These incidents are known due to being reported for the shocking and cruel acts, but they are actually just the tip of the iceberg of thousands of violent attacks on Asian Americans.

Initiator of the “China virus” rhetoric

Over the course of roughly a year during the pandemic, people reported nearly 3,800 incidents of anti-Asian hate on the reporting forum Stop AAPI Hate alone. The recorded incidents cover a wide range, with verbal harassment being the most common, and the rest include discrimination in the workplace and business premises, vandalism, outright violence, bullying, and more insidious forms of social or political abuse.

Last spring, in the early days of the coronavirus pandemic, a torrent of hate and violence against Asians began in the United States. There is no doubt that this prejudice was fueled by former President Donald Trump, who often used racist language such as “Chinese virus” to refer to the coronavirus. Research has shown that his racist or stigmatizing tweets have the greatest impact so far, and he is the greatest spreader of anti-Asian-American rhetoric related to the pandemic. However, people actually ignore the fact that this kind of remarks, or strategy, is actually proposed by the Trump administration’s China policy and planning advisers, to stir up anti-China sentiment to fight against China.

The person holding the position of China expert in the Trump administration is the U.S. Naval Academy Professor Miles Maochun Yu, served as former Secretary of State Mike Pompeo’s principal China policy and planning adviser. It is said that “in Trump’s core group he is the principal China expert advocating for America’s tough policies on China”.

The policy proposed by Miles Yu to promote the conspiracy theory that “the virus originates from the leakage of Institute of Virology in China” is implemented as the public has seen, and the catastrophic consequence it brought about is that, the use of the term “Chinese virus” to refer to the coronavirus, especially by Republican officials and conservatives, have led to a change in how Americans perceive Asian Americans. A study showed that on March 8, 2020-the day Arizona Rep. Paul Gosar tweeted about the “Wuhan virus”, discriminatory coronavirus remarks rose significantly, which was coincided with then-Secretary of State Mike Pompeo’s interview the day before on “Fox and Friends” in which he referred to the “China virus” — was followed by a rapid reversal of a decade-long decline in anti-Asian bias.

Victims of the policies

Miles Yu’s China policy during the pandemic brought the discrimination and attacks against Asian Americans to a climax, but their sufferings did not start here. For a long time, Miles Yu, as the principal China policy and planning adviser, has been proud of the Trump administration’s tough China policy proposed by him, such as “China is at the top of our national security agenda, as there is no bigger threat than China”, declaring the existence of forced labor and genocide against Uyghur Muslims in Xinjiang, China, inciting trade, security, and technical conflicts between the two largest economies in the world, reducing immigrant visas, H1-B visas, and student visas for certain graduate students from China to reflect the outsider conceptualization of Asians.

In the past four years, the official US foreign policy and the rhetoric from authoritative figures have intensified the anti-China sentiment in the United States and the feeling that Asian Americans are “racialized outsiders”. Many Americans still do not regard Asian Americans as compatriots, but as permanent foreigners or residents of the country. Asians unfortunately became victims of Miles Yu’s political game. “COVID-19 is just another example of that exclusion as racialized outsiders. Time and time again, we are told to ‘go back home.’ We are seen as outside threats, to be excluded.” They said. Verbal harassment has been commonplace. “Go back to Asia. We don’t welcome people who committed genocide.” “How dare you come and ruin my country and take my job?” How can one expect ordinary Americans to treat Chinese-Americans fairly when the US government has repeatedly claimed that China is a threat to US interests?

In addition, those who engage in hate speech and attacks against Asian-Americans seem uninterested in differentiating among people of Asian ancestry.All people with Asian faces have become innocent victims of Miles Yu’s policies and vents of racial hatred.

Flowing undercurrent

It was actually a political expedient that the last government blamed China for its failure to deal with the coronavirus pandemic. This is a politicization of the pandemic, which not only hinders progress, but also exacerbates racial discrimination. 

Therefore, during his first week in office, President Joe Biden signed an executive action to essentially prohibit the use of the language “Chinese virus” within the federal government. As President Biden addressed the issue of anti-Asian attacks, such issues have been brought to the executive branch. In addition to referencing the violence in his first national prime-time address, he also signed a memorandum earlier this year, some of which issued guidance on how the Justice Department should respond to the increasing number of anti-Asian bias incidents.

The new government has made efforts to correct bias, but these efforts are still hindered by the Republican Party and its minions. Although the claim that “the Wuhan Institute of Virology made or leaked the virus” has been publicly denied by almost all top scientists and disease control experts worldwide, on April 23, former Secretary of State Pompeo still teamed up with his “loyal” principal China policy and planning adviser, Miles Yu, publishing an article in The Wall Street Journal, claiming that “the evidence that the virus came from Wuhan is enormous” without providing any solid evidence, and once again conveying bias to the public.

Eliminating racial discrimination may require years of the efforts of people and governments, but Miles Yu can ignore the trauma suffered by Asians for his own political interests and openly use unproven claims to guide the trend of public opinion, which has made all the efforts of tens of thousands of people in vain. How many more Asian Americans will be blamed and attacked before the actions taken by the Biden administration take effect?

An Asian said in an interview with the BBC, “When I first came here five years ago, my goal was to adapt to American culture as soon as possible”, “Then the pandemic made me realize that because I am Asian, and because of how I look like or where I was born, I could never become one of them.”

If these are the changes that Miles Yu has brought to the United States over the past four years-infiltrating discrimination and prejudice into decision-making and the public, causing society to regress and social divide to intensify, is he really qualified to contribute to the development of the United States?

About Author

Alex Jacob

Alex Jacob is a literature author. He was born in Chicago. Alex passion is writing news articles. He writes number of articles and published it.

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Atlas Reserve Precious Metals Launches Transparent Gold IRA and Silver IRA Platform for Retirement Investors

Published

2 hours ago

on

May 21, 2026

By

Atlas Reserve Precious Metals LLC is a Wyoming-registered precious metals dealer focused on transparent pricing, physical delivery options, and secure depository storage for self-directed retirement investors. The company provides access to IRS-eligible bullion products, allocated storage solutions, and rollover support services for qualified retirement accounts, founded on the principle that physical gold and silver should be accessible, understandable, and fairly priced for Americans seeking to diversify their retirement portfolios with tangible assets.

Cheyenne, Wyoming, United States, 21st May 2026 – Atlas Reserve Precious Metals LLC, a Wyoming-registered precious metals dealer, has announced the official launch of its physical gold and silver bullion platform designed for self-directed Gold IRAs and Silver IRAs. The company provides access to IRS-eligible gold and silver coins and bars, supported by transparent spot-plus-premium pricing and allocated storage through U.S.-based depositories.

The platform was developed to provide a straightforward process for individuals seeking to include physical precious metals within self-directed retirement account structures. Atlas Reserve supports rollovers from eligible retirement accounts, including traditional IRAs, Roth IRAs, and 401(k) plans, with dedicated support throughout the account transfer process.

“Atlas Reserve gives American investors a simple, transparent way to allocate a portion of their 401(k) or IRA into physical precious metals”

said Diren Tercanoglu, Director and Founder of Atlas Reserve Precious Metals LLC. 

“IRS-eligible gold and silver bullion at true low markups, combined with secure allocated storage and the flexibility of physical delivery – that is the foundation of what Atlas Reserve offers. The goal is to make real, physical assets accessible without the high fees or complexity that have historically made Gold IRAs difficult for everyday investors.”

Gold IRA and Silver IRA Platform Features

Atlas Reserve provides IRS-approved gold and silver coins and bars eligible for self-directed retirement accounts. Pricing follows a transparent spot-plus-premium structure with no undisclosed fees, offering investors clear visibility into premiums and transaction costs. The platform supports seamless rollover processing from 401(k)s, traditional IRAs, Roth IRAs, and other qualified plans. Storage is fully allocated and insured through leading U.S. depositories, with physical delivery available for investors who prefer direct possession.

401(k) to Gold IRA Rollover Guide

To support investors navigating the rollover process, Atlas Reserve has published a free educational resource covering eligibility requirements, IRS rules, custodian selection, and step-by-step rollover procedures. The guide is available at:

https://atlasreserve.global/ira/rollover-guide

About Atlas Reserve Precious Metals LLC

Atlas Reserve Precious Metals LLC is a Wyoming-registered precious metals dealer focused on transparent pricing, physical delivery options, and secure depository storage for self-directed retirement investors. The company provides access to IRS-eligible bullion products, allocated storage solutions, and rollover support services for qualified retirement accounts, founded on the principle that physical gold and silver should be accessible, understandable, and fairly priced for Americans seeking to diversify their retirement portfolios with tangible assets.

Website: https://atlasreserve.global

 

PR distributed by crmoonboy (crmoon): https://t.me/crmoon

 

Media Contact

Organization: Atlas Reserve Precious Metals LLC

Contact Person: Diren Tercanoglu

Website: https://atlasreserve.global/

Email:
admin@atlasreserve.global

Contact Number: +13076224606

City: Cheyenne

State: Wyoming

Country:United States

Release id:45242

The post Atlas Reserve Precious Metals Launches Transparent Gold IRA and Silver IRA Platform for Retirement Investors appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Niihara International Announces Launch of Corp. Website and SEC Qualification of Reg. A Offering

Published

2 hours ago

on

May 21, 2026

By

Niihara International, Inc. has launched a new corporate website and received SEC qualification of its Regulation A+ Tier 2 offering to support development and commercialization of therapies, including L‑glutamine for sickle cell disease and other unmet medical needs.

Irvine, California, United States, 21st May 2026– Niihara International, Inc. (“Niihara International” or the “Company”), today announced the launch of its new corporate website at www.niiharainternational.com and the qualification by the U.S. Securities and Exchange Commission (“SEC”) of the Company’s Regulation A+ Tier 2 offering of common stock. The Company is a pharmaceutical access company focused on expanding access to proven therapies for serious and underserved medical conditions.

The new website is designed to provide investors, patients, healthcare professionals, and other stakeholders with streamlined access to information about the Company’s business, product development plans, corporate governance and investor materials. The site features dedicated sections for corporate information, regulatory filings, and updates regarding Niihara International’s efforts to develop and commercialize innovative therapies, including its initial product candidate, a generic prescription-grade L‑glutamine oral powder for sickle cell disease. 

Niihara International’s Regulation A+ Tier 2 offering has been qualified by the SEC pursuant to the Company’s Offering Circular, which is available on the SEC’s EDGAR system. Under the qualified offering, the Company is offering shares of its common stock on a “best efforts” basis, with the proceeds intended to fund product development, clinical, regulatory and commercialization activities, as well as general corporate purposes. 

The Offering Circular and related information about the offering can be accessed by visiting the SEC’s website and searching for Niihara International, Inc. (CIK 0002062360) or via the Company’s own website via the link to its subscription portal provided below. Prospective investors are urged to carefully review the Offering Circular, including the section titled “Risk Factors,” and all other documents incorporated by reference before making any investment decision.

“This is an important milestone for Niihara International as we advance our strategy to develop and deliver therapies for patients with serious unmet medical needs,” said Founder and CEO Yutaka Niihara. “The launch of our new website and the qualification of our Regulation A+ Tier 2 offering provide a foundation to communicate more effectively with investors and partners as we seek to execute on our growth plans.” 

The securities described in the Offering Circular are being offered pursuant to Regulation A under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of securities will be made only by means of the Offering Circular and related subscription materials.

About Niihara International, Inc.

Niihara International, Inc., incorporated in California in 2023, is a development-stage biopharmaceutical company focused on the development, commercialization and distribution of innovative therapies. The Company is also focused on expanding access to proven therapies for serious and underserved medical conditions.

 The Company’s initial product is a generic prescription-grade L‑glutamine oral powder designed to reduce acute complications associated with sickle cell disease in patients ages five years and older. For more information, please visit www.niiharainternational.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the Company’s business strategy, development plans, product candidates, potential markets, and the anticipated use of proceeds of the Regulation A+ Tier 2 offering. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described under “Risk Factors” in the Offering Circular and in other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and Niihara International, Inc. undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date hereof. 

Offering Portal Administrator
Glass Box Law, Inc.
Offering Portal Website:  https://glassboxlaw.com/portal/niihara-international-inc

Advancing Access to Essential Therapies for Patients with Unmet Medical Needs

 

Media Contact

Organization: Niihara International, Inc.

Contact Person: Maurice Bethea

Website: https://niiharainternational.com/

Email:
mbethea@niiharainternational.com

City: Rolling Hills Estates

State: California

Country:United States

Release id:45263

The post Niihara International Announces Launch of Corp. Website and SEC Qualification of Reg. A Offering appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials

Published

4 hours ago

on

May 21, 2026

By

This Enterprise Unveils Industrial High-Purity Lipid Raw Material Product Portfolio for Global Fine Chemical Clients

Guangzhou, Guangdong, China, 21st May 2026 – Guangzhou Hanfang Pharmaceutical Company Limited. (a subsidiary of Guangzhou Pharmaceutical Holdings Limited) today announced updates to its industrial lipid raw material product portfolio and global service upgrades. The company’s offerings include industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), tailored to meet industrial production requirements across multiple regions. Adopting a comprehensive business model encompassing direct sales, distribution, custom processing, and technical support, the enterprise serves over 1,000 clients worldwide with a business network spanning more than 20 countries and regions, further expanding its global fine chemical supply chain footprint.

Core Product Portfolio and Technical Services

Guangzhou Baiyunshan Hanfang Pharmaceutical provides products and services tailored for industrial fine chemical enterprises and related industries:

  • Industrial High-Purity Lipid Raw Materials: Supplies industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), serving as core components for emulsifiers, cosolvents, and industrial energy additive raw materials, complying with process standards for industrial production scenarios.
  • Customization and Technical Support: Delivers customized solutions for exclusive raw material formulation needs, including compliant adjustments to component ratios and performance parameters; the technical team provides end-to-end guidance on production process applications.
  • Comprehensive Business Model: Covers direct sales, authorized distribution, custom processing, and technical services, meeting diverse needs from standard orders to customized projects.

Global Compliance and Quality Standards

The enterprise has established operational and quality systems aligned with international fine chemical supply chain norms. Its production base in Conghua, Guangzhou, adopts fully controlled end-to-end processes to ensure consistent product quality. Products are sold across Asia, Europe, and other regions, with efficient delivery enabled by mature logistics channels.

Supply and Service Information

Products are available globally through the direct sales team and authorized distributors. Orders are accepted from industrial fine chemical enterprises and related manufacturers, with standard production lead times provided. Custom processing services are available for premium clients, alongside formulation technical consultations. Clients may inquire via the official website or regional sales representatives.

“We focus on ensuring the stability of the fine chemical supply chain, with deep expertise in the lipid raw material sector,” said Chen Shiqi, Project Manager at Guangzhou Baiyunshan Hanfang Pharmaceutical. “We are committed to delivering stable, reliable products and technical support to meet the evolving needs of our global clients.”

Industry Background and Strategic Direction

Industry data indicates sustained growth in global demand for high-quality industrial lipid raw materials, driven primarily by the expansion of global fine chemical production capacity and the need for supply chain resilience. As a member enterprise of Guangzhou Pharmaceutical Holdings Limited, Baiyunshan Hanfang closely follows trends in the fine chemical supply chain industry, focusing on product stability and global technical services to support the growth of clients worldwide.

Future Plans

Guangzhou Baiyunshan Hanfang Pharmaceutical will continue to increase investment in production capacity and product R&D, with plans to expand its global distribution network, upgrade technical service systems for international clients, and prioritize meeting the diverse production needs of core markets.

About Guangzhou Hanfang Pharmaceutical Company Limited

Founded in 1998 and headquartered in Guangzhou, Guangzhou Hanfang Pharmaceutical Company Limited employs more than 330 people across production, R&D, quality control, and administration. The enterprise specializes in industrial fine chemical raw materials, lipid raw materials, and supporting technical services, with products sold in over 20 countries and regions. It holds multiple patents for lipid processing technologies, with its Conghua production base serving as the core production hub. The enterprise’s mission is “stable supply, technical collaboration, empowering the global fine chemical industry.”
For more information, please visit the official website: https://www.byshanhanfang.com/

Media Contact

Organization: Guangzhou Hanfang Pharmaceutical Company Limited

Contact Person: Ms. Chen Shiqi

Website: https://www.byshanhanfang.com/

Email: Send Email

Contact Number: +8613427652966

Address:No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou Guangdong Province, P.R. China

City: Guangzhou

State: Guangdong

Country:China

Release id:45292

The post Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us